170015-99-3 Usage
General Description
4-(Trifluoromethoxy)phenylethyl amine is a chemical compound with the molecular formula C9H10F3NO. It is an organic compound that belongs to the class of phenethylamines. The compound is characterized by the presence of a trifluoromethoxy group attached to a phenyl ring, which is further connected to an ethylamine moiety. 4-(Trifluoromethoxy)phenylethyl amine has potential applications in the field of medicinal chemistry and drug development, as well as in the synthesis of various organic compounds. Its unique structure and functional groups make it a valuable building block for the development of new pharmaceuticals or organic materials with desired properties. Additionally, its trifluoromethoxy group contributes to its potential use as a fluorinated building block for the development of agrochemicals or materials with enhanced properties and stability.
Check Digit Verification of cas no
The CAS Registry Mumber 170015-99-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,0,0,1 and 5 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 170015-99:
(8*1)+(7*7)+(6*0)+(5*0)+(4*1)+(3*5)+(2*9)+(1*9)=103
103 % 10 = 3
So 170015-99-3 is a valid CAS Registry Number.
InChI:InChI=1/C9H10F3NO/c10-9(11,12)14-8-3-1-7(2-4-8)5-6-13/h1-4H,5-6,13H2
170015-99-3Relevant articles and documents
17a-HYDROXYLASE/C17,20-LYASE INHIBITORS
-
Paragraph 0848, (2014/03/21)
The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.
A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST
-
Page/Page column 85, (2008/06/13)
The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.
TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
-
Page/Page column 87, (2010/02/07)
The present invention is directed to compounds of the formula I: I(wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.
